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Background and Purpose  Epidemiologic data suggest that cluster headache (CH) is sig-
nificantly associated with cigarette smoking. The aim of this study was to determine differ-
ences in features between patients with a smoking history and those who are never-smokers, 
using data from a prospective multicenter registry. 
Methods  Data used in this study were obtained from the Korean Cluster Headache Registry 
that collected data from consecutive patients diagnosed with CH. We compared clinical and 
demographic features between ever-smokers (current or former smokers) and never-smokers.
Results  This study enrolled 250 patients who were diagnosed with CH, of which 152 (60.8%) 
were ever-smokers and 98 (39.2%) were never-smokers. The age at CH onset was significantly 
lower in the never-smoker group than in the ever-smoker group [27.1±12.9 years vs. 30.6± 
10.9 years (mean±standard deviation), p=0.024]. Seasonal rhythmicity (58.1% vs. 44.7%, p= 
0.038) and triptan responsiveness (100% vs. 85.1%, p=0.001) were higher in never-smokers, 
while other clinical features such as pain severity, duration, attack frequency, and associated 
autonomic symptoms did not differ significantly between the groups. The male-to-female ra-
tio was markedly higher in ever-smokers (29.4:1) than in never-smokers (1.7:1). 
Conclusions  Most of the clinical features did not differ significantly between patients with 
a smoking history and never-smokers. However, the age at CH onset, sex ratio, and seasonal 
rhythmicity were significantly associated with smoking history. 
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Smoking History and Clinical Features of Cluster Headache: 
Results from the Korean Cluster Headache Registry
INTRODUCTION
Cluster headache (CH) is an excruciating form of primary headache that is characterized 
by recurrent unilateral headache attacks accompanied by ipsilateral autonomic features.1,2 
Salient features of CH are its male predominance, circadian rhythmicity, and trigeminal au-
tonomic features. CH is significantly associated with cigarette smoking, which is unique 
among all primary headache disorders,3-6 but a satisfactory explanation for this relationship 
or pathogenetic association has not been established. Numerous studies have indicated that 
the prevalence of cigarette smoking is high in the CH population, with up to 90% of males 
and 70% of females being smokers.7-11 Secondary smoke exposure during childhood may 
trigger CH even in nonsmokers.12 Distinct clinical features between smokers and nonsmok-
ers or between those exposed and not exposed to smoking have rarely been reported. Re-
cent population-based studies noted that patients with CH who are not exposed to smoking 
develop CH at a lower age than do those who are exposed to smoking.3,13 There is also in-
creasing evidence that smoking affects the disease severity. Several studies have indicated 
that smoking is associated with more-severe CH phenotypes, such as a longer bout duration, 
higher attack frequency, and higher pain severity.3,5,14,15 However, a study investigating the ef-
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fect of smoking cessation on CH found that the condition of 
patients rarely improves after they stop cigarette smoking.14 
The above-described situation means that it remains ques-
tionable how the close association between CH and smoking 
should be interpreted. Furthermore, studies investigating dif-
ferences in clinical and demographic features between smok-
ers and nonsmokers are scarce, especially in Asian populations. 
Therefore, the aim of this study was to identify differences be-
tween ever-smokers (current and former smokers) and never-
smokers using data from the Korean Cluster Headache Reg-
istry (KCHR), which prospectively enrolled patients with CH.
METHODS
Patients
This study was conducted using data from the KCHR, which 
is a multicenter, cross-sectional registry that prospectively col-
lected data from consecutive patients with CH who visited 
the neurology outpatient departments of 16 hospitals in Ko-
rea between August 2016 and December 2018. Board-certi-
fied neurologists who specialize in headache at each hospital 
conducted the study. 
All participants were evaluated by board-certified neurol-
ogists in each center to confirm that the diagnosis fulfilled the 
criteria of the third edition (beta version) of the International 
Classification of Headache Disorders (ICHD-3β) for CH.16 
Participants who met the criteria for definite CH or probable 
CH were identified for inclusion in this study. Their final in-
clusion was based on the criteria of ICHD-3, since those cri-
teria were published during the course of this project.2 
The study protocol and informed consent form were ap-
proved by the institutional review board at each hospital (Dong-
tan Sacred Heart Hospital, IRB 2016-09-396). Written informed 
consent was obtained from all participants before they were 
enrolled in this study. This study was conducted in accordance 
with the principles of the Declaration of Helsinki.
Clinical information
Data obtained and used in the study included the following: 
demographic factors, age, age at onset, headache characteris-
tics, seasonal and diurnal rhythmicity, and treatment response. 
Clinical information regarding current headache episodes in-
cluded the location, severity, duration, and frequency of head-
ache attacks; autonomic symptoms; and diurnal rhythmicity. 
The previous history of CH included the time since the first 
CH attack, total number of cluster bouts, and pattern of sea-
sonal periodicity. Triptan responsiveness was defined as a 
reduction of ≥50% in pain intensity compared to the usual 
pain intensity according to the patient’s judgement. The per-
sonal history of cigarette smoking was obtained and used to 
classify patients into ever-smokers and never-smokers. Ever-
smoker patients were further classified into current and for-
mer smokers. 
Statistical analysis
Demographics and clinical features were compared between 
ever-smokers and never-smokers. The two-sample t-test and 
Mann-Whitney U-test were used to compare the mean val-
ues between ever-smokers and never-smokers, according to 
whether or not each variable conformed to a normal distribu-
tion based on the Kolmogorov-Smirnov test. The chi-square 
test or Fisher’s exact test was used to compare categorical vari-
ables. Probability values of p<0.05 were considered indicative 
of statistical significance. All analyses were performed using 
the Statistical Package for the Social Sciences (version 24.0, 
IBM Corp., Armonk, NY, USA).
RESULTS 
Characteristics of patients 
One of the 251 patients identified as having CH based on ICHD-
3β was excluded for not meeting the criteria of ICHD-3. Of the 
remaining 250 patients ultimately enrolled in this study, 176 
were classified as having episodic CH, 12 were classified as 
having chronic CH, 27 were classified as having probable CH, 
and the remaining 35 who met the criteria of CH but had the 
first episode of CH without a determined remission period or 
recurrence were classified as having first CH (Table 1).17 The 
male-to-female ratio was 5.1:1, with 209 male and 41 female 
patients. The 250 patients comprised 152 (60.8%) ever-smok-
ers and 98 (39.2%) never-smokers. The prevalence of smok-
ing differed significantly with sex, with 70.3% of male patients 
and 12.2% of female patients being ever-smokers. The 152 ev-
er-smokers comprised 96.7% (n=147) males and 3.3% (n=5) 
females, yielding a male-to-female ratio of 29.4:1. In the never-
smoker group, the male-to-female ratio was 1.7:1 (n=62 vs. 
36), while 49.8% of males and 12.2% of females were current 
smokers. 
We compared different features between the ever-smoker 
and never-smoker groups. The age at the time of investiga-
tion was 35.0±11.3 years (mean±standard deviation; range 
18–79 years) for the never-smokers and 39.7±9.7 years (range 
21–69 years) for the ever-smokers (p<0.001) (Table 1). The age 
at onset was significantly lower in never-smokers than in ever-
smokers (27.1±12.9 years vs. 30.6±10.9 years, p=0.024). Simi-
larly, the distribution of onset age differed between the never-
smokers and ever-smokers, with a tendency toward a lower 
age at onset in the never-smoker group (p=0.033) (Fig. 1). The 
prevalence of migraine history was higher in never-smokers 
(21.4%) than in ever-smokers (9.9%), which might reflect a 
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higher migraine prevalence in females. Chronic CH was rare 
in both groups, with no significant intergroup difference (5.9% 
vs. 3.1%, p=0.234). Multivariable logistic analysis suggested 
that male sex (OR=32.01, 95% CI=8.02–127.78), higher age 
at CH onset (OR per year=1.04, 95% CI=1.01–1.08), and al-
cohol drinking (OR=2.37, 95% CI=1.22–4.61) were indepen-
dently associated with an ever-smoker history (Supplemen-
tary Table 1 in the online-only Data Supplement).
Headache characteristics
The clinical features of CH were comparable between ever-
smokers and never-smokers, without significant differences 
in the characteristics of pain or cluster bouts (Table 2). The 
severity of current headache attack as assessed using a nu-
meric rating scale from 0 to 10 did not differ between the ever-
smokers and never-smokers (9.0±1.2 vs. 9.0±1.2). There was 
also no significant difference between the ever-smokers and 
never-smokers in the duration of each attack (107.6±122.6 
minutes vs. 97.0±75.6 minutes, p=0.459), daily attack frequen-
cy (2.1±1.7 vs. 2.1±1.9, p=0.835), total number of cluster bouts 
since the first attack, or the reported presence of diurnal rhyth-
micity. However, seasonal rhythmicity was reported more 
frequently by never-smokers than by ever-smokers (58.1% 
vs. 44.7%, p=0.038). 
Overall, 153 patients reported the efficacy of triptans dur-
ing headache attacks. Because triptan formulations of nasal 
spray or subcutaneous injections are currently not available 
in Korea, all triptan use was via oral formulations. Triptan ef-
fectiveness (defined as a reduction of ≥50% in pain intensity) 
was reported in 89.2% (74/87) of ever-smoker patients and 
100% (66/66) of never-smokers (p=0.001), suggesting a more-
favorable response to triptans in the never-smoker population. 
Lacrimation and conjunctival injection were the most fre-
quently reported autonomic symptoms both in ever-smokers 
Table 1. Comparison of demographics between the ever-smoker and never-smoker groups
All (n=250) Ever-smokers (n=152) Never-smokers (n=98) p
Male 209 (83.6) 147 (96.7) 62 (63.3) <0.001
Age, years 37.9±10.5 (18–79) 39.7±9.7 (21–69) 35.0±11.3 (18–79) <0.001
Subtypes of CH 0.234
ECH 176 110 66
CCH 12 9 3
PCH 27 12 15
fCH 35 21 14
Onset age, years 29.3±11.9 (9–78) 30.6±10.9 (10–62) 27.1±12.9 (9–78) 0.024
CH history, years 8.6±7.9 (0–39) 9.1±8.2 (0–39) 7.9±7.4 (0–32) 0.228
Migraine history 36 (14.4) 15 (9.9) 21 (21.4) 0.011
Current alcohol drinking 140/236 (59.3) 101/146 (69.1) 39/90 (43.3) <0.001
Data are mean±standard deviation (range), n, or n (%) values. fCH was CH that could not be classified as either ECH or CCH because a participant’s 
CH was their first bout and persisted for less than 1 year or did not recur after the first bout. fCH, ECH, CCH and PCH were defined as codes 3.1, 3.1.1, 
3.1.2, and 3.5 in the third edition of the International Classification of Headache Disorders.
CCH: chronic CH, CH: cluster headache, ECH: episodic CH, fCH: first CH, PCH: probable CH.






Headache severity, NRS 9.0±1.2 9.0±1.2 0.968
Attacks per day 2.1±1.7 2.1±1.9 0.835
Attack duration, minutes 107.6±122.6 97.0±75.6 0.459
Total number of bouts 11.9±14.3 10.9±16.2 0.637
Triptan effectiveness 74/87 (85.1) 66/66 (100) 0.001
Diurnal rhythmicity 81 (53.3) 57 (58.1) 0.449
Seasonal rhythmicity 68 (44.7) 57 (58.1) 0.038
Bouts duration, weeks 6.3±7.1 5.7±5.8 0.542
HIT-6 score 67.6±8.3 68.9±7.8 0.224
GAD-7 score 7.95±5.51 7.40±6.31 0.483
PHQ-9 score 7.54±5.99 7.68±7.02 0.862
Data are mean±standard deviation or n (%) values.
GAD-7: Generalized Anxiety Disorder-7, HIT-6: Headache Impact Test-





































≤20 21–30 31–40 41–50 ≥51
Fig. 1. Distributions of ages at onset of cluster headache in ever-
smokers and never-smokers.
232  J Clin Neurol 2021;17(2):229-235
Smoking and Cluster HeadacheJCN
(86.2%) and never-smokers (78.6%), with no significant dif-
ferences (p=0.116). Other cranial autonomic symptoms also 
did not differ significantly between the groups (Table 3).
Current smokers versus never-smokers and former 
smokers
We further compared the characteristics between current smok-
ers and never-smokers and between current smokers and for-
mer smokers (Table 4). The age at CH onset differed between 
current smokers and never-smokers, and the effect of triptan 
was again better for never-smokers than for current smokers. 
However, other clinical characteristics did not differ between 
current smokers and never-smokers, and so the differences 
between current smokers and never-smokers were consis-
tent with those between ever-smokers and never-smokers. 
There were no significant differences between current smok-
ers and former smokers.
DISCUSSION
The main findings of this study were as follows: 1) The age at 
CH onset was lower in never-smokers than in ever-smokers 
(current or former smokers). 2) Most of the clinical features 
of CH did not differ significantly between never-smokers and 
ever-smokers, with the exception that never-smokers expe-
rienced more favorable triptan responses and higher seasonal 
rhythmicity. 3) The male-to-female ratio was much lower in 
never-smokers than in ever-smokers (1.7:1 vs. 29.4:1).
The hypothalamus is involved in the pathogenesis of CH.1,18 
Primary headache disorders such as migraine,19 short-lasting 
neuralgiform headache attacks with conjunctival injection 
and tearing,20 and paroxysmal hemicrania21 are also consid-
ered to be disorders that are modulated by the hypothalamus. 










Eyelid edema 35 32 0.093
Ptosis 27 25 0.141




Forehead/facial sweating 61 30 0.127
Restlessness/agitation 76 43 0.344
No autonomic symptom 3 6 0.086
Table 4. Comparison of current, former, and never-smokers
Current smoker (n=109) Former smoker (n=43) Never-smoker (n=98) p* p†
Male 104 (95.4) 43 (100) 62 (63.3) <0.001 0.153
Age, years 39.2±9.2 41.2±10.7 35.0±11.3 0.004 0.254
Onset age, years 30.0±10.1 32.1±12.7 27.1±12.9 0.075 0.338
Subtypes of CH 0.468 0.305
ECH 80 30 66
CCH 4 5 3
PCH 9 3 15
fCH 16 5 14
CH duration, years 9.2±7.8 9.1±9.4 7.9±7.4 0.233 0.946
Migraine history 8 (7.3) 7 (16.3) 21 (21.4) 0.004 0.096
Current alcohol drinking 70/104 (67.3) 31/42 (73.8) 39/90 (43.3) 0.001 0.441
Severity, NRS 9.0±1.2 9.0±1.2 9.0±1.2 0.973 0.847
Attacks per day 1.9±1.6 2.5±1.8 2.1±1.9 0.376 0.051
Attack duration, minutes 104.2±139.9 116.6±83.7 97.0±75.6 0.655 0.592
Total number of bouts 12.1±15.1 11.4±12.1 10.9±16.2 0.620 0.829
Triptan effectiveness 58/65 (89.2) 16/22 (72.7) 66/66 (100) 0.006 0.061
Diurnal rhythmicity 60 (55.1) 21 (48.8) 57 (58.2) 0.651 0.490
Seasonal rhythmicity 49 (45.0) 19 (44.1) 57 (58.2) 0.058 0.932
Bouts duration, weeks 5.8±6.2 7.5±9.1 5.7±5.8 0.894 0.247
HIT-6 score 68.0±8.2 66.6±8.5 68.9±7.8 0.440 0.330
Data are mean±standard-deviation, n, or n (%) values.
*p value between current smokers and never-smokers, †p value between current smokers and former smokers.
CCH: chronic CH, CH: cluster headache, ECH: episodic CH, fCH: first CH, HIT-6: Headache Impact Test-6, NRS: numeric rating scale from 0 to 10, PCH: 
probable CH.
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Toxic chemicals from cigarette smoking may alter hypothal-
amus-based neurotransmitter function, leading to the devel-
opment of CH in susceptible patients. Although the relation-
ship between migraine and smoking is controversial,22 CH is 
peculiar in its strong association with cigarette smoking, and 
numerous studies have revealed an epidemiologic association 
between CH and smoking.4,5,7,8,23,24 Some studies have even 
shown that secondary smoke exposure during childhood may 
be related to the subsequent development of CH.12 However, 
the mechanism underlying the pathogenetic role of cigarette 
smoking in the development of CH has not been clarified.25
In the prospectively maintained KCHR, 60.8% of patients 
were ever-smokers and 39.2% were never-smokers, while 70.3% 
of males (147/209) and 12.2% (5/41) of females were ever-
smokers. The proportion of ever-smokers was lower than in 
previous reports. The smoking rate was 83.9% among the 
population included in an Italian study conducted from 1975 
to 1980, but sex differences in smoking prevalence were not 
reported for that study.7 Bahra et al.8 reported that 89% of 
males and 71% of females were former or current smokers, 
while 84% of males and 65% of females were current or for-
mer smoker in a German study.9 Males were more likely to 
have a smoking history than were females (75% vs. 69%, p= 
0.02) in a US study involving a CH survey.10 A large observa-
tional study involving 590 subjects in Italy found a smoking 
rate of 90% in males and 59% in females.11 Overall, 75–90% 
of male patients and 59–71% of female patients in Western 
studies have had a smoking history. Smoking habits in Asian 
populations have been rarely reported, but one Taiwanese 
study found that 78.9% of male patients and 35.7% of females 
were ever-smokers, while 63.3% of males and 28.6% of females 
were current smokers.26 
We found that the proportions of both male and female 
patients with CH who were ever-smokers were lower than in 
previous studies. This finding might reflect a decrease in the 
smoking population influenced by strict contemporary smoke-
free regulations in Korea and worldwide, or there may be some 
ethnicity differences in the association between smoking and 
CH in different populations. According to Korean Statistical 
Information Service, the prevalence of a current smoking habit 
in Korean male aged >19 years decreased from 66.3% in 1998 
to 36.7% in 2018, while it did not change among Korean fe-
male (6.5% in 1998 and 7.5% in 2018).27
The male-to-female ratio was much lower in never-smok-
ers than in ever-smokers (1.7:1 vs. 29.4:1), which is probably 
due to the high proportion of male smokers in the general 
population. However, this discrepancy in sex ratio between 
smokers and never-smokers was greater in our CH cohort 
than the estimated sex ratio of smokers in the general pop-
ulation. Although the male-to-female ratio of the ever-smok-
er population was much higher in the present study than in 
Western studies, the sex ratio in the never-smoker population 
was similar to that found in Western and Taiwanese studies 
(1.5–2:1).9,11,26 Recent data suggest that the male predomi-
nance of the CH prevalence has decreased, especially in West-
ern studies.28,29 Identifying the associations and causality of 
the changing sex ratio of CH (increasing prevalence in fe-
males) and changing smoker ratios over time requires fur-
ther large cohort studies.  
Recent studies showed that CH patients not exposed to 
smoking or who were never-smokers are significantly more 
likely to develop CH at a lower age than exposed patients (in-
cluding to secondary smoke exposure) and ever-smokers.3,13 
Consistent with previous reports, our study also found that 
the age at CH onset was lower in never-smokers than in ever-
smokers. In addition, seasonal rhythmicity was more frequent 
among never-smokers in our study. The lower age at onset in 
the never-smoker group suggests a genetic or biology-based 
etiology, while the higher age at onset in ever-smokers is sug-
gestive of the consequences of smoke exposure.3 However, a 
lower age at CH onset could cause patients to avoid smoking, 
so the influence of smoking before and after the onset of CH 
needs to be investigated further.
While other studies have suggested that the symptoms of 
CH are more severe in smokers,3,5,14 our study did not find 
such a relationship, with indeed most of the clinical features 
not differing significantly between the groups. The treatment 
response to oral triptan seems more favorable in never-smok-
ers; however, other studies have found no differences in trip-
tan responses between groups,3 or that triptan has a better 
treatment effect in patients with a smoking history.5 There-
fore, the reports of treatment responses according to smok-
ing habits have been inconsistent.  
One study found that autonomic symptoms and agitation 
are more common in smoking-exposed patients,3 but we found 
no difference in cranial autonomic symptoms between ever-
smokers and never-smokers. 
The significance of smoking for the pathophysiology of CH 
remains unknown. Nicotine affects trigeminal nociception 
in healthy people,30 increases the release of calcitonin-gene-
related peptide in many tissues,31 and could trigger the acti-
vation of the trigeminal autonomic reflex in the brainstem, 
causing cranial autonomic symptoms of CH.32 Also, nicotine 
and other toxic agents act on the hypothalamus or cortex and 
may consequently cause CH.25 Smoking may therefore be a 
risk factor for the development of CH, but the latency between 
smoking onset and CH onset was too long to suspect a direct 
causal relationship (mean 15.6 years).5 Furthermore, smoking 
cessation was not found to improve CH.14 Therefore, a causal 
relationship between smoking and CH remains to be proven.
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There are several limitations to this study. First, detailed 
information regarding smoking habits such as the amount 
of cigarette smoking, debut age of smoking, and exposure to 
second-hand smoke were not available in this registry-based 
study. Second, the participants in this study consisted only of 
patients referred to a secondary or tertiary hospital, and so 
the results might not be generalizable to all patients with CH, 
especially those with milder forms of the disorder. Third, al-
though smoking was suggested to be a risk factor for chron-
ic CH,3 we were unable to evaluate this association since the 
proportion of subjects with chronic CH was very low. Fourth, 
we defined triptan responsiveness according to patients’ re-
call of a subjective reduction in pain intensity of >50%. Since 
the treatment responsiveness was assessed only using a ques-
tionnaire based on patients’ recall, individual attacks of CH 
are very short, and triptan use was only reported in 153 of 250 
patients, the association between the smoking pattern and 
triptan response should be interpreted cautiously.
In conclusion, this study found that the age at CH onset, 
sex ratio, and seasonal rhythmicity are significantly associat-
ed with a history of smoking. The later onset of CH among 
ever-smokers than never-smokers suggests the smoking acts 
as a secondary environmental contributor to CH.
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